Response to Letter Regarding Article, Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT
[摘要]
[发布日期] [发布机构]
[效力级别] [学科分类]
[关键词] TRIALS [时效性]
